Trinity College Dublin


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Dr. Stephen Finn

Associate Professor Consultant (Histopathology)

 


Dr. Stephen Finn MB BAO BCh FDS PhD FRCPath FFPATH, is a Associate Professor, Consultant Pathologist and Principal Investigator at The University of Dublin, Trinity College and at St. James's Hospital Dublin, a tertiary referral cancer institution. He is co-director of the Cancer Molecular Diagnostic Laboratory, the only fully accredited molecular diagnostic laboratory in Ireland. His clinical practice is limited to Urological, Gastrointestinal and Liver pathology. Dr. Finn is former Senior Scientist and Staff Pathologist to the Centre for Molecular Oncologic Pathology at the Dana Farber Cancer Institute, Boston, USA. Dr. Finn continues to have strong personal and collaborative links to the Harvard School of Public Health, the Dana Farber Cancer Institute and the University of Orebro in Sweden. Dr. Finn is a member of the Irish Prostate Cancer Research Consortium (PCRC) and the Transdisciplinary Prostate Cancer Partnership ToPCaP. Dr. Finn, a current recipient of the Prostate Cancer Foundation Young investigator Award, and is committed to forging a career as an independent researcher focused on prostate cancer and bringing his skills as a clinician, pathologist and scientist to bear on critical questions of clinical relevance to men who suffer from aggressive prostate cancer.
  ARCHIVAL MATERIAL   BETA-CATENIN   Cancer Molecular Diagnostics   Cancer/Carcinogenesis   CATENIN COMPLEX   Diagnostic bioimaging   DIAGNOSTIC LABORATORIES   DIGESTIVE TRACTS   DISSECTION   E-CADHERIN   EPITHELIAL-CELLS   FROZEN SECTION   GASTRIC CARCINOMAS   GENE   H4 D10S170   HASHIMOTO THYROIDITIS   HEAD AND NECK CANCER   Imaging Techniques   Lipid metabolism   Lung Cancer   NECK DISSECTION   Obesity   ORAL CAVITY   PAPILLARY THYROID CARCINOMA   Pathology   PATTERNS   Prostate cancer   RATIONALE   RET PROTOONCOGENE   RET/PTC-1   SQUAMOUS-CELL-CARCINOMA   STAGING   STAGING PROCEDURE   TAQMAN RT-PCR   TYROSINE PHOSPHORYLATION
 Identifying non-coding RNA repertoires of aggressive Prostate cancer
 EXPECT Trial: Evasion of immune editing by circulating tumour cells is an exercise-modifiable mechanism underlying aggressive behaviour in obese men with prostate cancer
 Discovery and Clinical Implementation of Novel Predictive Biomarkers for Enzalutamide therapy

Details Date
Chairman Molecular Pathology, Faculty of Pathology, RCPI 01/02/2011
Details Date From Date To
Fellow of the Royal College of Pathologists 2005 Current
Nur MM, Finn S, Reynolds JV, Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells., Expert review of anticancer therapy, 14, (3), 2014, p267-9 , Journal Article, PUBLISHED  DOI
O'Brien CP, Taylor SE, O'Leary JJ, Finn SP, Molecular testing in oncology: Problems, pitfalls and progress., Lung cancer (Amsterdam, Netherlands), 2014, Journal Article, PUBLISHED  TARA - Full Text
O'Brien CP, Langabeer SE, O'Byrne KJ, O'Leary JJ, Finn SP, Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns., Molecular diagnosis & therapy, 18, (1), 2014, p1-4 , Journal Article, PUBLISHED  DOI
Hayes BD, Finn SP, Kidney volume correlates with tumor diameter in renal cell carcinoma and is associated with histological poor prognostic features., International journal of surgical pathology, 22, (1), 2014, p39-46 , Journal Article, PUBLISHED
Guevara G, O'Connor E, McCormack O, Harmon M, Finn S, Muldoon C, Ravi N, Reynolds JV, Diffuse oesophageal leiomyomatosis., ANZ journal of surgery, 2013, Journal Article, PUBLISHED  DOI
Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA, Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG., Journal of the National Cancer Institute, 105, (24), 2013, p1881-90 , Journal Article, PUBLISHED
Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA, Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 22, (12), 2013, p2354-63 , Journal Article, PUBLISHED
Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E, Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 22, (11), 2013, p1984-93 , Journal Article, PUBLISHED
Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M, Gleason grade progression is uncommon., Cancer research, 73, (16), 2013, p5163-8 , Journal Article, PUBLISHED
Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA, Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening., International journal of molecular sciences, 14, (1), 2013, p2085-103 , Journal Article, PUBLISHED
  

Page 1 of 6